Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions
Tianzhong Li,Jingfeng Li,Zhi Chen,Shaohui Zhang,Shunling Li,Zhongjian Xie,Ranjith Kumar Kankala,Han Zhang,S. Wageh,Omar A. Al-Hartomy,Abdullah G. Al-Sehemi
DOI: https://doi.org/10.1016/j.jconrel.2022.09.065
IF: 11.467
2022-12-01
Journal of Controlled Release
Abstract:Glioma is often referred to as one of the most dreadful central nervous system (CNS)-specific tumors with rapidly-proliferating cancerous glial cells, accounting for nearly half of the brain tumors at an annual incidence rate of 30-80 per a million population. Although glioma treatment remains a significant challenge for researchers and clinicians, the rapid development of nanomedicine provides tremendous opportunities for long-term glioma therapy. However, several obstacles impede the development of novel therapeutics, such as the very tight blood-brain barrier (BBB), undesirable hypoxia, and complex tumor microenvironment (TME). Several efforts have been dedicated to exploring various nanoformulations for improving BBB permeation and precise tumor ablation to address these challenges. Initially, this article briefly introduces glioma classification and various pathogenic factors. Further, currently available therapeutic approaches are illustrated in detail, including traditional chemotherapy, radiotherapy, and surgical practices. Then, different innovative treatment strategies, such as tumor-treating fields, gene therapy, immunotherapy, and phototherapy, are emphasized. In conclusion, we summarize the article with interesting perspectives, providing suggestions for future glioma diagnosis and therapy improvement.
pharmacology & pharmacy,chemistry, multidisciplinary